Actively Recruiting
Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment
Led by Centre Hospitalier Universitaire, Amiens · Updated on 2025-06-04
150
Participants Needed
1
Research Sites
230 weeks
Total Duration
On this page
Sponsors
C
Centre Hospitalier Universitaire, Amiens
Lead Sponsor
C
Central Hospital Saint Quentin
Collaborating Sponsor
AI-Summary
What this Trial Is About
In the last decades, cancer treatment was based on surgery, radiotherapy and chemotherapy. Recently, treatments have largely evolved, first with targeted therapies (notably tyrosin kinase inhibitors, TKI) and then with immune checkpoint inhibitors (ICPI, notably anti-CTLA-4 and anti- PD1). The last ones can induce durable anti-tumoral responses in patients, even if metastases are present. Their mechanisms of action are focused on the activation of immune system in order to eliminate the tumor. ICPI, because of their mechanisms of action, target immune tolerance key components and can induce important immune toxicities (colitis, hepatitis, dermatitis, thyroiditis ...), leading to early discontinuation of treatment, severe or chronic morbidity, and can sometimes be lethal. It is of importance to detect patient at risk of irAEs, because of the increasing use of ICPI and the long- term response capacity in treated patients.
CONDITIONS
Official Title
Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient with cancer, any tumor type and disease stage, currently under immune checkpoint inhibitor treatment (anti-PD1 and/or anti-CTLA-4)
- Age over 18 years
- Receiving care in oncology, pneumology, dermatology, or gastroenterology departments of Amiens-Picardie University Hospital or Saint Quentin hospital
- Provided verbal and written information and signed consent form for the study
You will not qualify if you...
- Not receiving immune checkpoint inhibitor treatment
- Received a first line of immune checkpoint inhibitor treatment
- Currently receiving or previously received MEK inhibitors as treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU Amiens Picardie
Amiens, Picardie, France, 80054
Actively Recruiting
Research Team
G
Gwladys BOURDENET, DR
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here